Brain Health

Symptoms of dementia can be difficult to differentiate from typical age-related behavior changes and other common and potentially curable conditions.

Failing to protect the elderly from disease has consequences beyond nursing homes.

In addition to improving risk evaluation in older adults at home, point-of-care testing may help clinicians manage patients with dementia who cannot communicate and those living in depopulated areas.

Heart health may influence long-term brain health as early as middle age.

This social determinant of health could have the same level of negative impact on health as the experience of racism, poverty, or low education.

The recent discovery could aid further research on the cause of Huntington’s disease and other inherited conditions.

UB-311 has shown to be well-tolerated with a durable antibody response in a previous phase 1 trial, and new results from a phase 2a study support its continued development.

Investigators aimed to determine whether liraglutide, an anti-obesity medication, could impact the learning process for individuals who had reduced insulin sensitivity due to obesity.

Sleep loss is known to impact key processes such as attention, cognition, learning, memory, metabolism, and immune function.

Key study finding shows associations between the beat frequency in the rhythmic stimulus in the frontal left sites of infant brains and pathways related to brain modulation and nucleotide levels.

Advancements in the development of amyloid-targeting monoclonal antibodies show promise for treating Alzheimer disease, but there have been concerns around cost, adverse reactions, and inequity of care for marginalized patients.

Unexpectedly, the highest increases in delirium compared to projections were in the 66 to 74 years of age group, which could have important personal and societal repercussions, such as earlier development of dementia.

Adults aged 80 years and older and those living in areas with worse economic conditions are more likely to receive potentially inappropriate medications in the outpatient setting, which may be associated with cognitive impairment.

Nikhil Palekar discusses the FDA approval of lecanemab-irmb (Leqembi, Eisai) and what this means for those who have Alzheimer Disease.

Of the individuals that participated in the study, 65.3% reported hearing loss at 71 years and 96.2% reported hearing loss by 90 years.

The risk of death by suicide in soldiers was both directly and indirectly related to traumatic brain injury through confounding mental health diagnoses.

The study authors said that, to their knowledge, this will be the first systematic review focusing on the effects of cognitive interventions for those with chronic respiratory diseases.

Despite the improvements in the patients' symptoms, minor adverse effects including urinary urgency and liver-related issues were reported.

Pharmacists play a key role in the management of modern monoclonal antibody treatments for Alzheimer disease.

PT staff discusses health outcomes involving SABI, reduced vascular function, and OBA.

Exercise alone or vitamin D supplementation did not clinically improve cognition in adults with mild cognitive impairment.

New anti-amyloid monoclonal antibody drugs for Alzheimer disease have produced encouraging results in targeting the accumulation of amyloid beta plaques; however, questions remain regarding the risk-benefit profile and cost implications.

Notably, the risk of cognitive impairment among retired professional soccer players grows larger by position, with those such as forwards and defenders being most at risk.

Individuals with age-related hearing loss should not be treated with “standard” hearing aids, but fitted to their personal needs, while avoiding settings that add distortion.

Idiopathic intracranial hypertension was previously considered a rare condition, however, its prevalence is increasing in parallel with obesity in patient populations.